Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

NCT04811001 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

170

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Osimertinib
DRUG: Dacomitinib

Sponsor

Fondazione Ricerca Traslazionale